Treat Cancer at Any Stage

A Bold, Novel Drug Approach to Kill Tumors and Activate Immune Response

Treat locally, act globally. Intensity is developing proprietary intratumoral immunotherapy products that both directly kill injected solid tumors AND induce immune system recognition of cancer cells throughout the body to address the three challenges of cancer treatment: local, regional, and metastatic disease.

A Bold, Novel Drug Approach to Kill Tumors and Activate Immune Response to Treat Cancer at Any Stage

Treat locally, act globally. Intensity is developing proprietary intratumoral immunotherapy products that both directly kill injected solid tumors AND induce immune system recognition of cancer cells throughout the body to address the three challenges of cancer treatment: local, regional, and metastatic disease.

Tumor
Injection

DfuseRx℠ is our novel proprietary penetration enhancer platform technology that enables therapeutic agents to be injected directly into solid tumors for improved absorption.

Diffusion
Through Tumor

Once injected, DfuseRx enables the injected drug solution to disperse throughout the tumor and increases the drug’s diffusion into cancer cells.

Localized
Cell Death

The absorbed active agents in the injected tumor induce cancer cell death, without disruption of the cell membrane, in a manner that results in an influx of immune cells throughout the tumor.

System-wide
Immune Response

Tumor cell death exposes the immune system to antigens of the patient’s own cancer, inducing a personalized CD4+ and CD8+ T cell response, attacking the site of the former tumor while attacking distal cancer sites.

Increased
Survival

Exploratory analysis of data from a Phase 1/2 trial of relapsed and refractory solid tumor patients with a variety of cancers indicates an association between percent of tumor burden treated and survival.

Technology and Clinical Data

DfuseRxSM is our novel proprietary product discovery technology that enables drug compounds including cytotoxic agents to be injected directly into solid tumors with high absorption. The technology makes use of novel dispersion and cell penetration enhancer molecules that we have identified.
Play Video

Register for News Updates:

Subscribe to our company news email list and receive news as it is released. Your privacy is important, and your email address will be used only for this news distribution list.

Latest Tweets:

We’re excited to announce that we have refreshed the Intensity Therapeutics website today!

Go check it out: https://intensitytherapeutics.com/

A paper published last year in @MDPIOpenAccess illustrates how an amphiphilic molecule contained in our new drug INT230-6’s novel formulation can maximize its effectiveness as an #intratumoral treatment.

Read more: https://bit.ly/3pNR3dL

#SolidTumors

#Intratumoral delivery requires an understanding of the chemistry required for tumor and cancer cellular absorption post-injection, which is why INT230-6 has so far shown positive results in clinical testing where others have failed.

Aqueous #intratumoral injections without Intensity’s novel cell penetration enhancing technology are unlikely to be absorbed by the tumor and would be expected to leak out. In contrast, INT230-6 when injected into a tumor stays in the tumor.

There are many exciting things in store for us in 2021, and we look forward to elaborating on upcoming corporate and clinical milestones.

Load More...